ArticlemSphere2025
A dual-mechanism antimicrobial peptide with antimutagenic activity targets the replisome and induces cell envelope stress.
Amanda Holstad Singleton, Olaug Elisabeth Torheim Bergum, Jana Scheffold, Synnøve Brandt Ræder, Lilja Brekke Thorfinnsdottir, Lisa Marie Røst, Caroline Krogh Søgaard, Per Bruheim, Marit Otterlei
Abstract read
In one paragraphArticle in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Amanda Holstad Singleton *Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Olaug Elisabeth Torheim Bergum *Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Jana ScheffoldDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Synnøve Brandt RæderDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Lilja Brekke ThorfinnsdottirDepartment of Biotechnology and Food Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Lisa Marie RøstDepartment of Biotechnology and Food Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Caroline Krogh SøgaardDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Per BruheimDepartment of Biotechnology and Food Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Marit OtterleiDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.ORCID 0000-0002-5232-1186 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
To combat the growing threat of multidrug-resistant bacteria, we need to develop novel antibiotics with unique modes of action. This study investigates the antibacterial properties of BTP-001 toward
Indexed as
Anti-Bacterial AgentsAntimicrobial PeptidesCell MembraneDNA ReplicationEscherichia coliDNA Polymerase IIIEscherichia coli ProteinsMicrobial Sensitivity TestsReactive Oxygen SpeciesAnti-Bacterial AgentsAntimicrobial PeptidesDNA Polymerase IIIEscherichia coli ProteinsReactive Oxygen SpeciesantimutagenicAPIMcell-penetrating peptideEscherichia coliproteomicstranscriptomicsβ-clamp
Identifiers
PMID40879398
PMCPMC12482183
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390